Omicron
BioNTech —
Pfizer
the University of Washington
BA.1 or BA.2
Delta).In
BA.1 and BA.2
the Francis Crick Institute
LondonThe
Omicron BA.1
antibody’
the Vanderbilt University School of Medicine
Medical News Today
Jonathan Stoye
GAVI
William Schaffner
No matching tags
No matching tags
No matching tags
Wuhan
Alpha
Nashville
TN
U.S.
No matching tags
The rapidly developed vaccines are very successful in preventing severe illness, hospitalization, and death, but new variants still cause breakthrough infections in many people.Now, two preprint studies, which have not yet been peer-reviewed, have found evidence that a breakthrough Omicron infection can afford additional protection to those who are already vaccinated.A third, peer-reviewed study, has confirmed this finding.The first study, sponsored by BioNTech — which makes the Pfizer vaccine — found an increase in memory B cells and cross-variant neutralization after breakthrough infection. Unvaccinated individuals with Omicron infection showed limited neutralization of only Omicron.These findings concur with advice from GAVI — the vaccine alliance — that antibodies produced from previous Omicron infection in individuals who had been vaccinated against COVID-19 afforded greater protection against new variants than those from people who had recovered from natural infection alone.
As said here by Katharine Lang